Drug Trial Radar · NCT03971422
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Jun 3, 2019
Primary completion
Aug 31, 2021
Study completion Oct 26, 2021
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Jun 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG).
Conditions
- Generalized Myasthenia Gravis
Interventions
RozanolixizumabDrug
Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
PlaceboOther
Subjects will receive placebo at pre-specified time points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) ScoreTime frame: Baseline and Day 43
Locations
112 sites in 17 countries. Site status is shown where the registry gives one.
Mg0003 50081
Phoenix, Arizona
Mg0003 50082
Scottsdale, Arizona
Mg0003 50072
Los Angeles, California
Mg0003 50092
Orange, California
Mg0003 50097
San Francisco, California
Mg0003 50099
San Francisco, California
Mg0003 50101
Aurora, Colorado
Mg0003 50088
Washington D.C., District of Columbia
Mg0003 50122
Miami, Florida
Mg0003 50120
Miami, Florida
Mg0003 50073
Tampa, Florida
Mg0003 50075
Augusta, Georgia
Mg0003 50323
Honolulu, Hawaii
Mg0003 50109
Chicago, Illinois
Mg0003 50114
Indianapolis, Indiana
Mg0003 50074
Fairway, Kansas
Mg0003 50121
Lexington, Kentucky
Mg0003 50110
Ann Arbor, Michigan
Mg0003 50102
Detroit, Michigan
Mg0003 50104
Rochester, Minnesota
Mg0003 50105
St Louis, Missouri
Mg0003 50077
New York, New York
Mg0003 50117
Charlotte, North Carolina
Mg0003 50086
Charlotte, North Carolina
Mg0003 50090
Winston-Salem, North Carolina
Mg0003 50076
Columbus, Ohio
Mg0003 50096
Philadelphia, Pennsylvania
Mg0003 50089
Philadelphia, Pennsylvania
Mg0003 50084
Charleston, South Carolina
Mg0003 50113
Houston, Texas
Mg0003 40121
Brussels, Belgium
Mg0003 50067
Calgary, Canada
Mg0003 50066
Montreal, Canada
Mg0003 50070
Québec, Canada
Mg0003 50069
Toronto, Canada
Mg0003 40125
Ostrava, Czechia
Mg0003 40124
Prague, Czechia
Mg0003 40128
Aalborg, Denmark
Mg0003 40127
Aarhus N, Denmark
Mg0003 40126
Copenhagen, Denmark
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.